NEW YORK (GenomeWeb) – Members of the research and lab community believe liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, according to a recent survey of readers conducted by Frost & Sullivan in conjunction with GenomeWeb and analyzed by Divyaa Ravishankar, a senior industry analyst at Frost & Sullivan.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

Jul
19
Sponsored by
Philips Genomics

This webinar will provide an overview of how liquid biopsies can be integrated into lung cancer care.

Jul
20
Sponsored by
NuGEN

This webinar describes the characterization of gene fusions across distinct subtypes of melanoma.